Management

Duke Collier
Executive Chairman

Earl M. (Duke) Collier, Jr. is executive chairman of Arsenal Medical. He is also serving as chief executive officer of 480 Biomedical and a senior advisor to Polaris Venture Partners. For many years, Mr. Collier was executive vice president at Genzyme Corporation. He has also served as president of Vitas Healthcare, a partner at the Washington, DC-based law firm of Hogan and Hartson, and as deputy administrator of the Health Care Finance Administration (now CMS) in the Department of Health and Human Services. Mr. Collier sits on the boards of Arsenal Medical, Pervasis Therapeutics, Newton-Wellesley Hospital and the Boston Athenaeum. He earned a Bachelor of Arts at Yale University and received a law degree from the University of Virginia Law School.

James J. Barry, Ph.D.
Executive Vice President and Chief Operating Officer

James J. Barry, Ph.D., is executive vice president and chief operating officer of Arsenal Medical. Prior to Arsenal Medical, Dr. Barry held a variety of senior positions at Boston Scientific, most recently senior vice president of Corporate Technology Development where he oversaw corporate R&D and preclinical science. While at Boston Scientific, Dr. Barry initiated and led the company’s drug-eluting stent programs. Under Dr. Barry’s leadership, the TAXUS™ drug-eluting coronary stent was developed and became the most successful medical device ever launched, attaining annual sales exceeding $3 billion. Prior to joining Boston Scientific, Dr. Barry held positions at Howmedica and Kontron Instruments. Dr. Barry is the author of multiple articles in peer reviewed publications and holds more than 35 U.S. patents. He currently serves on the advisory boards of the Massachusetts Life Sciences Center, University of Massachusetts-Lowell College of Sciences and Yale University’s College of Biomedical Engineering. Dr. Barry holds a doctorate in biochemistry from the University of Massachusetts-Lowell and a Bachelor of Arts in chemistry from Saint Anselm College.

Toby Freyman, Ph.D.
Vice President, Research and Development

Prior to joining Arsenal Medical, Dr. Freyman was an associate principal with Charles River Associates (CRA) where he was involved in the launch of new bio-pharmaceutical products. Before CRA, Dr. Freyman was a principal engineer with Boston Scientific Corporation’s Corporate Research and Advanced Technology Development group.  In this capacity, he focused on the identification and development of combination products to treat cardiovascular diseases.  While at Boston Scientific, Dr. Freyman managed a group of senior-level scientists and established partnerships with leading academic and corporate collaborators.  Dr. Freyman has 12 scientific publications and presentations, 23 patents and 13 patent applications. He holds a doctorate in materials engineering from MIT, where he received a National Institutes of Health Graduate Fellowship through a joint program with Harvard and MIT.